What happened with NAUT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Nautilus Biotechnolgy, Inc. is developing Nautilus Voyager to help researchers identify and count proteins, including different forms of the same protein. The system is designed to repeatedly probe individual intact protein molecules and use machine learning to interpret the measurements. Its initial customers are laboratories at pharmaceutical and biotechnology companies and research institutions with established protein-analysis expertise.
The company has launched fee-for-service access through Nautilus Proteomics Analysis Services, initially offering the Nautilus Tau Proteoforms assay. Selected customers send samples to Nautilus for analysis and receive results through a cloud platform. Nautilus has not yet generated revenue and does not expect material revenue from this early-access program. Its longer-term plan is to let customers buy Voyager instruments for their own laboratories, then earn recurring revenue as they use consumables, subscribe to analysis software and purchase support.
The business depends on completing and validating this single platform, persuading researchers to adopt it and securing spending from their research budgets. Nautilus currently promotes its products primarily for research use, not clinical diagnosis. Marketing them for diagnostic or other medical uses could require regulatory clearance or approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Quantum-Si Incorporated already sells single-molecule protein-sequencing instruments to researchers, competing for the protein-characterization and proteoform budgets Nautilus's planned Voyager platform targets. Watch Platinum and Platinum Pro consumables revenue for evidence of continued sample testing on those instruments.
Seer, Inc. competes with Nautilus's planned Voyager platform for broad protein-profiling work at academic and biopharmaceutical laboratories. Its Proteograph suite sells researchers sample-processing consumables, automation and software for use with mass spectrometry; adoption by those laboratories is the customer overlap to watch.
Alamar Biosciences, Inc. sells protein-analysis instruments and disease-focused tests to the research and biopharmaceutical laboratories Nautilus hopes to serve. Adoption of its ARGO HT System and neurology assays is particularly relevant as Nautilus offers paid analysis of different forms of tau protein.
Quanterix Corporation competes for the same biopharmaceutical and academic laboratories as Nautilus, selling ultrasensitive protein-detection instruments, consumables and paid research services. Watch its neurology research business, where the customer overlap is particularly relevant to Nautilus's tau proteoform analysis service.
Bruker Corporation's protein-analysis instruments compete for laboratory equipment budgets that Nautilus's planned Voyager platform needs to win. Watch its proteomics instrument offerings to research and biopharmaceutical customers rather than treating its wider scientific-instrument business as a direct comparison.
Thermo Fisher Scientific's protein-analysis offerings, including Olink, compete with Nautilus's planned Voyager platform for academic and biopharmaceutical research budgets. Its protein-analysis business with those customers is more relevant to Nautilus than its broader sales of laboratory products and pharmaceutical services.
Illumina competes with Nautilus for researchers' protein-profiling work through its acquired SomaLogic business, not its core DNA-sequencing instruments and consumables. Sequencing contributed 92% of Illumina's total revenue in fiscal 2025, so SomaLogic developments give a more direct read on this rivalry than group revenue.
Waters sells laboratories mass spectrometry systems used to analyze proteins, competing with Nautilus's planned Voyager platform for proteomics instrument spending.
Agilent Technologies sells laboratories systems that separate samples and measure their molecules—liquid chromatography–mass spectrometry—competing with Nautilus's planned platform for proteomics spending. Watch those instrument sales rather than all CrossLab consumables, much of which Agilent sells regardless of the customer's instrument supplier.
Danaher competes with Nautilus for laboratories' protein-analysis work through SCIEX, but its wider biotechnology and diagnostics businesses dilute that exposure. SCIEX news is therefore more directly relevant to Nautilus's planned Voyager platform than Danaher's overall results.
Nautilus Biotechnolgy, Inc. earningsThis company
Nautilus has no commercial revenue yet, so this report will show whether its cash can keep funding Voyager's development and commercialization preparations.
Read operating cash use alongside cash and investments, and watch for updates on paid Tau sample analysis and Voyager's progress. Controlled cash use, continued platform progress and laboratories willing to pay for analyses would suggest Nautilus can keep moving toward commercialization before revenue scales; faster cash use, slow progress or weak customer interest would increase funding pressure.
Alamar Biosciences, Inc. earningsALMR
Alamar's report will show whether research laboratories are adopting its neurology assays, a relevant but not identical demand signal for Nautilus's paid Tau analysis service.
Look for reported adoption of Alamar's neurology assays, especially its tau-related work, rather than relying only on company-wide sales. Rising adoption would show laboratories are spending on neurology protein research, a supportive demand signal for Nautilus's Tau analysis service; weak adoption would leave that signal less encouraging. Alamar's assays are not Nautilus's proteoform analysis, so growth at Alamar would not establish orders for Nautilus.
Quantum-Si Incorporated earningsQSI
Quantum-Si's consumables sales will show whether researchers keep using its protein-sequencing instruments, a direct read on the budgets Nautilus is seeking for Voyager.
Compare consumables sales with instrument placements or the installed base, if reported. Placements accompanied by continued consumables growth would show that laboratories are repeatedly running samples and sustaining spending on a competing platform; placements without follow-on consumables, or falling consumables sales, would be weaker evidence of continued use and could mean less pressure on Nautilus for those budgets. Neither outcome proves demand for Voyager.
